ADIL - Adial Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9600
-0.0500 (-2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0100
Open1.9500
Bid1.9600 x 800
Ask2.0200 x 800
Day's Range1.9000 - 2.0300
52 Week Range1.1100 - 9.4400
Volume13,726
Avg. Volume73,034
Market Cap20.038M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.3210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that its Chief Medical Officer, Bankole Johnson, M.D., D.Sc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI, presented the Company's lead investigational new drug product, AD04, for the treatment of alcohol use disorder (AUD), at the Scientific Federation 7th World Congress on Nursing & Healthcare in London, England.

  • ACCESSWIRElast month

    Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the further strengthening of its intellectual property (IP) portfolio, as it has received a Notification Prior to Acceptance from the Israeli Intellectual Property Office on its patent for AD04, which covers the use of AD04 to treat certain genotypes for alcohol use disorder. William Stilley, CEO of Adial Pharmaceuticals, stated, "We are delighted to be awarded this patent as we believe the demographics and expected prevalence of the target genotype in Israel may support rapid adoption upon regulatory approval.

  • ACCESSWIRElast month

    Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization

    ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, and Tedor Pharma, Inc., a full-service contract development and manufacturing organization (CDMO), today announced that they entered into a collaboration agreement to provide cGMP contract manufacturing services for AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). Adial is on track to commence its first Phase 3 trial of AD04 next quarter and plans to conduct that trial using its current inventory of drug product.

  • ACCESSWIRE2 months ago

    Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder

    ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has entered into a collaboration agreement with Eurofins Scientific ("Eurofins"), a global scientific leader in bioanalytical testing, to provide the genetic testing during Adial Pharmaceutical's planned Phase 3 clinical trial ("Phase 3 Trial" or the "Trial"). The Phase 3 Trial is designed to study AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.

  • ACCESSWIRE3 months ago

    Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City

    CHARLOTTESVILLE, VA / ACCESSWIRE / April 30 , 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, ...

  • Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?
    Simply Wall St.3 months ago

    Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve...

  • ACCESSWIRE3 months ago

    Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that its Chief Medical Officer, Bankole Johnson, MD, a recent recipient of the American Society of Addiction Medicine's highest honor, was featured on WPTV-TV, the NBC affiliate in West Palm Beach, Florida. Dr. Johnson discussed the fight against alcohol use disorder (AUD), opioid addiction and the addiction epidemic.

  • ACCESSWIRE3 months ago

    Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the appointment of Alex Lugovoy as Head of Strategy. Mr. Lugovoy will further develop and advance the Company's corporate partnerships, licensing and mergers and acquisitions strategy.

  • ACCESSWIRE4 months ago

    Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award

    ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, announced that its Chief Medical Officer, Bankole Johnson, M.D., will be delivering the keynote lecture at the 50th Annual American Society of Addiction Medicine Conference on April 5th in Orlando, Florida. At the Conference, Dr. Johnson is also being recognized as ASAM's 2019 recipient of the R. Brinkley Smithers Distinguished Scientist Award.

  • ACCESSWIRE4 months ago

    Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI has purchased 73,100 shares of the Company's common stock in the open market over the March 28 and March 29 trading days as reported on a Form 4 that Dr. Johnson filed with the Securities and Exchange Commission. Adial Pharmaceuticals previously announced Dr. Johnson's appointment as Chief Medical Officer of the Company, and prior to becoming the Chief Medical Officer, he served as Chairman of the Board of the Company.

  • ACCESSWIRE4 months ago

    Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer

    NASDAQ: ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI has joined the Company as its Chief Medical Officer. In connection with this new position, Dr. Johnson will step down from the Board of Directors of Adial and from his position as Chairman, and will also leave his position as the Chair of the Department of Psychiatry at the University of Maryland to devote greater focus to his new duties with the Company.

  • ACCESSWIRE4 months ago

    Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed a Registration Statement on Form S-1 on March 22, 2019, to update certain information in the Registration Statement on Form S-1 that was declared effective on July 26, 2018. The Company is also seeking to register 125,000 shares of common stock under the Registration Statement on Form S-1 filed on March 22, 2019, in order to fulfill a contractual obligation to a prior holder of the Company's warrants and notes. The newly filed registration statement on Form S-1 is subject to review by the SEC before becoming effective.

  • Benzinga5 months ago

    Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner

    More than 15 million Americans suffer from alcohol use disorder, according to the CDC, but a new medication may offer a solution. This week, Adial CEO Bill Stilley discussed the prospects for AD04 in an interview with CBS San Francisco affiliate KPIX-TV.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Featured on CBS in San Francisco

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced that William Stilley, President and Chief Executive Officer, appeared on the CBS affiliate, KPIX-TV, “Bay Area Focus” morning show on Tuesday, February 26, 2019. Mr. Stilley discussed the Company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announces the closing of its previously announced underwritten public offering of 2,845,000 shares of its common stock and warrants to purchase up to 2,133,750 shares of the Company's common stock, which included 370,000 shares of common stock and warrants to purchase up to 277,500 shares of common stock issued upon the partial exercise of the underwriters’ option to purchase additional securities to cover over-allotments. Each share of common stock was sold together with a warrant to purchase 0.75 of one share of common stock at a combined price to the public of $3.25.The warrants are immediately exercisable at a price of $4.0625 per share of common stock (subject to adjustment) and will expire five years from the date of issuance Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $9.2 million.

  • ACCESSWIRE5 months ago

    Four Biotech Stocks Setting The Standard On Thursday (2/21/19)

    CORAL GABLES, FL/ ACCESSWIRE / February 21, 2019 / The future of the biotech stock market is dependent on whether medical experts have the ability to continue pioneering advancements in medicine and other innovative solutions to curing diseases. As companies in the biotech sector continue to develop medicines that address the significant needs of patients, these innovations could catalyze significant investor attention. Premier Health Group (PHGRF) (PHGI), AVEO Pharmaceuticals Inc (AVEO), Adial Pharmaceuticals Inc (ADIL), and Tenax Therapeutics Inc (TENX) represent four biotech stocks that are testing their limits on Thursday. Premier Health Group (PHGRF) (PHGI) is a Canadian publicly traded company strategically poised to take advantage of potential opportunities in the global healthcare industry.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock.  Each share of common stock is being sold together with a warrant to purchase 0.75 of one share of common stock at a combined price to the public of $3.25.  Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $8.0 million. The warrants will be immediately exercisable at a price of $4.0625 per share of common stock and will expire five years from the date of issuance.  The shares of common stock and the accompanying warrants can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance.  The offering is expected to close on or about February 25, 2019, subject to customary closing conditions.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced a partnership with Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, to advance clinical activities related to AD04, Adial’s genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder (“AUD”). This partnership brings together critical capabilities to allow the commencement of Adial’s planned initial Phase 3 trial, with Catalent providing packaging and distribution.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has submitted a continuation patent application with U.S. Patent and Trademark Office to broaden the claims relating to the use of AD04 for opioid dependence and abuse, commonly referred to as Opioid Use Disorder (OUD). William Stilley, CEO of Adial Pharmaceuticals, stated, “Given the progress we are making advancing towards our Phase 3 trial for AD04 in Alcohol Use Disorder (AUD), we are now accelerating our efforts to expand into other indications.

  • GlobeNewswire5 months ago

    Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

    ADILW) http://www.adialpharma.com/, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has appointed Professor Markus Heilig, MD, PhD as a Scientific Advisory Board (SAB) member. The SAB is charged with helping to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.

  • GlobeNewswire5 months ago

    Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award

    The award recognizes and honors an individual who has made highly meritorious contributions in advancing the scientific understanding of alcoholism, its prevention and treatment. The Award and lecture will be presented at ASAM’s 50th Annual Conference in April, 2019.

  • GlobeNewswire6 months ago

    Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder

    ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that William Stilley, President and Chief Executive Officer, will appear today on the KSWB-TV FOX 5 Morning News in San Diego at 10:40 AM ET/7:40 AM PT. Additionally, he is scheduled to appear on the KPIX-TV (CBS-CW) “Bay Area Focus” morning show on February 3 during the 2:00 PM ET/11:00 AM PT hour.

  • GlobeNewswire6 months ago

    Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants

    Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has received $1.2 million in capital through the voluntary exercise of previously outstanding warrants to purchase 243,100 shares of its common stock.  Additionally, 125,000 shares were issued as part of the cashless exercise of warrants. “We remain focused on the operations and milestones related to our Phase 3 clinical trial of AD04 for Alcohol Use Disorder and AD04’s initial development for Opioid Use Disorder.

  • What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)?
    Simply Wall St.6 months ago

    What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)?

    If you want to know who really controls Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...

  • GlobeNewswire6 months ago

    Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder

    ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has appointed Professor Tomáš Zima, MD, DSc, Dr.h.c. Doctors Zima and Mueller bring broad and diversified experience in areas such as addiction, genetics and the diagnosis and treatment of alcohol related diseases. The SAB is charged with helping to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.